LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: ANSWER: Annotation Software for Electronic Reporting.

    Raulerson, Chelsea / Jimenez, Guillaume / Wakeland, Benjamin / Villa, Erika / Sorelle, Jeffrey / Malter, James / Gagan, Jeffrey / Cantarel, Brandi

    JCO clinical cancer informatics

    2022  Volume 6, Page(s) e2100113

    Abstract: Purpose: To better use genetic testing, which is used by clinicians to explain the molecular mechanism of disease and to suggest clinical actionability and new treatment options, clinical next-generation sequencing (NGS) laboratories must send the ... ...

    Abstract Purpose: To better use genetic testing, which is used by clinicians to explain the molecular mechanism of disease and to suggest clinical actionability and new treatment options, clinical next-generation sequencing (NGS) laboratories must send the results into reports in PDF and discrete data element format (HL7). Although most clinical diagnostic tests have set molecular markers tested and have a set range of values or a binary result (positive or negative), the NGS genetic test could examine hundreds or thousands of genes with no predefined list of variants. Although there are some commercial and open-source tools for clinically reporting genomics results for oncology testing, they often lack necessary features.
    Methods: Using several available software tools for data storage including MySQL and MongoDB, database querying with Python, and a web-based user application using JAVA and JAVA script, we have developed a tool to store and query complex genomics and demographics data, which can be manually curated and reported by the user.
    Results: We have developed a tool, Annotation SoftWare for Electronic Reporting (ANSWER), that can allow molecular pathologists to (1) filter variants to find those meeting quality control metrics in the genes that are clinically actionable by diagnosis; (2) visualize variants using data generated in the bioinformatics analysis; (3) create annotations that can be reused in future reports with association specific to the gene, variant, or diagnosis; (4) select variants and annotations that should be reported to match the details of the case; and (5) generate a report that includes demographics, reported variants, clinical actionability annotation, and references that can be exported into PDF or HL7 format, which can be electronically sent to an electronic health record.
    Conclusion: ANSWER is a tool that can be installed locally and is designed to meet the clinical reporting needs of a clinical oncology NGS laboratory for reporting.
    MeSH term(s) Computational Biology/methods ; Electronics ; Genetic Variation ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Software
    Language English
    Publishing date 2022-01-13
    Publishing country United States
    Document type Journal Article
    ISSN 2473-4276
    ISSN (online) 2473-4276
    DOI 10.1200/CCI.21.00113
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A Case Report of Breakthrough Infections With 2 SARS-CoV-2 Variants in a Lung Transplant Patient.

    Mahan, Luke D / Mohanka, Manish R / Joerns, John / Lawrence, Adrian / Bollineni, Srinivas / Kaza, Vaidehi / Timofte, Irina / La Hoz, Ricardo M / Sorelle, Jeffrey / Terada, Lance S / Kershaw, Corey D / Torres, Fernando / Banga, Amit

    Transplantation proceedings

    2022  

    Abstract: A lung transplant (LT) patient developed 2 distinct episodes of COVID-19, confirmed by whole-genome sequencing, which was caused by the Delta, and then followed 6 weeks later, by the Omicron variant. The clinical course with Omicron was more severe, ... ...

    Abstract A lung transplant (LT) patient developed 2 distinct episodes of COVID-19, confirmed by whole-genome sequencing, which was caused by the Delta, and then followed 6 weeks later, by the Omicron variant. The clinical course with Omicron was more severe, leading us to speculate that Omicron may not be any milder among LT patients. We discuss the potential mechanisms behind the Omicron not being any milder among LT patients and emphasize the need for outcomes data among these patients. Until such data become available, it may be prudent to maintain clinical equipoise as regards the relative virulence of the newer variants among LT patients.
    Language English
    Publishing date 2022-07-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 82046-5
    ISSN 1873-2623 ; 0041-1345
    ISSN (online) 1873-2623
    ISSN 0041-1345
    DOI 10.1016/j.transproceed.2022.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.

    Takita, Morihito / Matsumoto, Shinichi / Shimoda, Masayuki / Chujo, Daisuke / Itoh, Takeshi / Sorelle, Jeffrey A / Purcell, Kerri / Onaca, Nicholas / Naziruddin, Bashoo / Levy, Marlon F

    Clinical transplantation

    2012  Volume 26, Issue 5, Page(s) E471–84

    Abstract: Background: Islet cell transplantation (ICT) is a promising approach to cure patients with type 1 diabetes. We have implemented a new immunosuppression protocol with antithymoglobulin plus anti-inflammatory agents of anakinra and eternacept for ... ...

    Abstract Background: Islet cell transplantation (ICT) is a promising approach to cure patients with type 1 diabetes. We have implemented a new immunosuppression protocol with antithymoglobulin plus anti-inflammatory agents of anakinra and eternacept for induction and tacrolimus plus mycophenolate mofetil for maintenance [T-cell depletion with anti-inflammatory (TCD-AI) protocol], resulting in successful single-donor ICT.
    Methods: Eight islet recipients with type 1 diabetes reported adverse events (AEs) monthly. AEs were compared between three groups: first infusion with the TCD-AI protocol (TCD-AI-1st) and first and second infusion with the Edmonton-type protocol (Edmonton-1st and Edmonton-2nd).
    Results: The incidence of symptomatic AEs within the initial three months in the TCD-AI-1st group was less than in the Edmonton-1st and Edmonton-2nd groups, with a marginally significant difference (mean ± SE: 5.5 ± 0.3, 7.5 ± 0.5, and 8.3 ± 1.3, respectively; p = 0.07). A significant reduction in liver enzyme elevation after ICT was found in the TCD-AI-1st group compared with the Edmonton-1st and Edmonton-2nd groups (p < 0.05). Because of AEs, all patients in the Edmonton protocol eventually converted to the TCD-AI protocol, whereas all patients tolerated the TCD-AI protocol.
    Conclusions: TCD-AI protocol can be tolerated for successful ICT, although this study includes small cohort, and large population trial should be taken.
    MeSH term(s) Adult ; Antirheumatic Agents/therapeutic use ; Cohort Studies ; Combined Modality Therapy ; Diabetes Mellitus, Type 1/therapy ; Etanercept ; Female ; Humans ; Immunoglobulin G/therapeutic use ; Immunosuppression ; Immunosuppressive Agents/therapeutic use ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Islets of Langerhans Transplantation ; Lymphocyte Depletion ; Male ; Maximum Tolerated Dose ; Middle Aged ; Prognosis ; Receptors, Tumor Necrosis Factor/therapeutic use ; T-Lymphocytes/immunology
    Chemical Substances Antirheumatic Agents ; Immunoglobulin G ; Immunosuppressive Agents ; Interleukin 1 Receptor Antagonist Protein ; Receptors, Tumor Necrosis Factor ; Etanercept (OP401G7OJC)
    Language English
    Publishing date 2012-10-12
    Publishing country Denmark
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 639001-8
    ISSN 1399-0012 ; 0902-0063
    ISSN (online) 1399-0012
    ISSN 0902-0063
    DOI 10.1111/ctr.12011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top